Muhammad Sadeqi Nezhad is a cancer researcher at Clinical and Translational Science Institute (CTSI), University of Rochester Medical Center, New York, USA. Currently, he is working with a great team on development of cancer therapeutics for pancreatic cancer patients with primary and metastatic tumors at Wilmot Cancer Institute. One of his research desires is to develop novel therapeutic approaches for cancer patients with metastatic tumor cells.
Besides the cancer research, He, as an entrepreneur, is seeking to find pains in his research area to design and develop a novel therapeutic technology with great unmet market need. Currently, He is working at Office of Technology Transfer (UR Venture) of University of Rochester Medical Center with a professional business team as an Assistant in Technology Licensing and Marketing.
Muhammad has worked with several state-of-the-art and sophisticated Technologies.
His Areas of Expertise Are:
1. CRISPR/Cas9 Technology (Knock-In, Knock-out, and Knock-down)
2. Viral production (Lentivirus, Retrovirus, and Adeno Associated Virus)
3. short/small hairpin RNA (shRNA)
4. Biotin Ligase or BioID Technology, a Tool for Protein-Proximity Labeling in Living Cells
5. Degron Technology for discovering and validating new disease targets
6. Molecular Cloning
7. Electroporation, Transfection, and Transduction
8. Orthotopic Tumor Model Development
9. And, Many more routine lab experiments and techniques, such as PCR, RT-PCR, Flow Cytometry, Western Blot, etc.
He is also a Review Editor on the Editorial Board of Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers (specialty section of Frontiers in Oncology).
He also performed peer review for more than 40 times, and He has been a Peer Reviewer of the following Journals:
1. Cell Press, STAR protocols
2. Springer Nature, Stem Cell Reviews and Reports (IF: 6.43)
3. Frontiers in Immunology (IF: 7.561)
4. Elsevier, Biomedicine & Pharmacotherapy (IF: 7.419)
5. Cambridge University Press, Expert Reviews in Molecular Medicine (IF: 5.233)
6. Elsevier, Computers in Biology and Medicine (IF: 4.589)
7. As well as other prominent scientific Journals
He also participated in a research topic development for “Frontiers in Immunology” journal with eminent researchers from MD Anderson Cancer Center, Emory and Texas Med School. And the research topic led to 8 publications.